These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6104907)

  • 21. Bromocriptine in the treatment of parkinsonism.
    Parkes JD
    Drugs; 1979 May; 17(5):365-82. PubMed ID: 37066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug therapy of parkinsonism].
    Teräväinen H; Larsen TA
    Duodecim; 1982; 98(11):892-900. PubMed ID: 6125373
    [No Abstract]   [Full Text] [Related]  

  • 23. [Chemotherapy of Parkinson disease with agents other than L-DOPA or dopamine agonists].
    Kuno S
    Nihon Naika Gakkai Zasshi; 1994 Apr; 83(4):581-4. PubMed ID: 7963994
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 25. New drugs in the treatment of Parkinson's disease. An introduction.
    Bracco F
    Adv Neurol; 1996; 69():513-7. PubMed ID: 8615173
    [No Abstract]   [Full Text] [Related]  

  • 26. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacology of Parkinson's disease.
    Burton K; Calne DB
    Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antiparkinsonian drugs (author's transl)].
    Ando K
    No To Shinkei; 1980 Aug; 32(8):743-53. PubMed ID: 7008813
    [No Abstract]   [Full Text] [Related]  

  • 31. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroprotective therapy in Parkinson disease.
    Chen S; Le W
    Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
    Jackson JA; Jankovic J; Ford J
    Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
    Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D
    Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pergolide versus bromocriptine.
    Login IS
    Neurology; 1984 Feb; 34(2):258. PubMed ID: 6538025
    [No Abstract]   [Full Text] [Related]  

  • 38. Biochemical aspects of Parkinson's disease.
    Nagatsu T
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract]   [Full Text] [Related]  

  • 39. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
    [No Abstract]   [Full Text] [Related]  

  • 40. [Selective inhibitors of 2 types of monoamine oxidase and new possibilities of their therapeutic use].
    Knoll J
    Orv Hetil; 1982 May; 123(22):1335-44. PubMed ID: 7110688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.